Literature DB >> 26966628

Can Vemurafenib Induce Vitiligo in Metastatic Melanoma Patients?

Ricardo Ruiz-Villaverde1, Daniel Sánchez-Cano2.   

Abstract

Entities:  

Year:  2016        PMID： 26966628      PMCID： PMC4767302          DOI： 10.5152/balkanmedj.2015.15157

Source DB:  PubMed          Journal:  Balkan Med J        ISSN： 2146-3123            Impact factor:   2.021


× No keyword cloud information.
  4 in total

1.  Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma.

Authors:  Leticia Alonso-Castro; Luis Ríos-Buceta; Sergio Vano-Galvan; Carmen Moreno; Ainara Soria-Rivas; Pedro Jaén
Journal:  J Am Acad Dermatol       Date:  2013-07       Impact factor: 11.527

2.  Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study.

Authors:  P Quaglino; F Marenco; S Osella-Abate; N Cappello; M Ortoncelli; B Salomone; M T Fierro; P Savoia; M G Bernengo
Journal:  Ann Oncol       Date:  2009-07-21       Impact factor: 32.976

3.  Vitiligo and melanoma-associated hypopigmentation (MAH): shared and discriminative features.

Authors:  Anke Hartmann; Christina Bedenk; Petra Keikavoussi; Jürgen C Becker; Henning Hamm; Eva-Bettina Bröcker
Journal:  J Dtsch Dermatol Ges       Date:  2008-05-07       Impact factor: 5.584

Review 4.  Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality?

Authors:  Maya Ram; Yehuda Shoenfeld
Journal:  Ann N Y Acad Sci       Date:  2007-09       Impact factor: 5.691
  4 in total
  1 in total

1.  Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy.

Authors:  Francesca Consoli; Ausilia Maria Manganoni; Salvatore Grisanti; Fausto Petrelli; Marina Venturini; Giovanni Rangoni; Francesco Guarneri; Paolo Incardona; William Vermi; Pier Giacomo Calzavara Pinton; Alfredo Berruti
Journal:  PLoS One       Date:  2019-04-02       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.